Explore All Access
Check if your research matches the topics covered in Anti-Cancer Drugs?
- Degree of match
- Common matching concepts
- Additional journal recommendations
Anti-Cancer Drugs : Impact Factor & More
eISSN: 1473-5741pISSN: 0959-4973
Share this on:
Check your submission readiness
Find out how your manuscript stacks up against 24 technical compliance and 6 language quality checks.
Aims and Scope
Anti-Cancer Drugs is an international medical journal, which aims to promote and encourage research on anti-cancer agents. It was first published in 1990 and it includes reports on clinical and experimental research results, from conventional cytotoxic chemotherapy to hormonal or biological response modalities. The journal has 10 issues per year and the current editor in chief is Mels Sluyser. According to the 2014 Journal Citation Reports, the journal has an impact factor of 1.784, ranking it 164th out of 211 in the category Oncology and 162nd out of 254 in the category Pharmacology & Pharmacy. Less
Anti-Cancer Drugs Key Metrics
CiteScore 
5.2
H-Index
98
Impact Factor
< 5
SJR
Q3Oncology
SNIP
0.52
Topics Covered on Anti-Cancer Drugs
Cell growth
Colorectal cancer
Overall survival
Lung cancer
Hepatocellular carcinoma
Vinpocetine
Cisplatin
Cell cycle
Reactive oxygen species
Toxicity
Epidermal growth factor receptor
Squamous cell lung cancer
Hysterectomy
Breast cancer
Autophagy
Polymeric nanoparticles
Glioblastoma
Diffuse large B-cell lymphoma
Western blot
Tyrosine kinase
Anti-Cancer Drugs Journal Specifications
| Overview | |
| Publisher | LIPPINCOTT WILLIAMS & WILKINS |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1990 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Anti-Cancer Drugs ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Anti-Cancer Drugs
Utidelone plus pembrolizumab as the fourth-line combination treatment in non-small cell lung cancer with EGFR mutation: a case report.
- 18 Oct 2024
- Anti-cancer drugs
Prophylactic role of pentoxifylline against paclitaxel-induced neuropathy among patients with breast cancer: a randomized-controlled trial.
- 16 Oct 2024
- Anti-cancer drugs
SMAC mimetic BV6 acts in synergy with mTOR inhibitor to increase cisplatin sensitivity in ovarian cancer.
- 16 Oct 2024
- Anti-cancer drugs
Combination of anlotinib and sintilimab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma: a single-arm prospective study
- 8 Oct 2024
- Anti-Cancer Drugs
Hyper-late major response after 5 years of nivolumab: role of treatment beyond progression in head and neck cancer.
- 1 Oct 2024
- Anti-cancer drugs
Individualized medication of venetoclax based on therapeutic drug monitoring in Chinese acute myeloid leukemia patients using an HPLC method.
- 1 Oct 2024
- Anti-cancer drugs
Utidelone plus pembrolizumab as the fourth-line combination treatment in non-small cell lung cancer with EGFR mutation: a case report.
- 18 Oct 2024
- Anti-cancer drugs
Prophylactic role of pentoxifylline against paclitaxel-induced neuropathy among patients with breast cancer: a randomized-controlled trial.
- 16 Oct 2024
- Anti-cancer drugs
SMAC mimetic BV6 acts in synergy with mTOR inhibitor to increase cisplatin sensitivity in ovarian cancer.
- 16 Oct 2024
- Anti-cancer drugs
Combination of anlotinib and sintilimab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma: a single-arm prospective study
- 8 Oct 2024
- Anti-Cancer Drugs
Hyper-late major response after 5 years of nivolumab: role of treatment beyond progression in head and neck cancer.
- 1 Oct 2024
- Anti-cancer drugs
Individualized medication of venetoclax based on therapeutic drug monitoring in Chinese acute myeloid leukemia patients using an HPLC method.
- 1 Oct 2024
- Anti-cancer drugs
Compare Similar Journals with Anti-Cancer Drugs
Select Journals to Compare with Anti-Cancer Drugs
Total journals - 10
You can select up to 3 Journals at a time
Frontiers in Oncology
Publisher: FRONTIERS MEDIA SA
Cancer Research
Publisher: AMER ASSOC CANCER RESEARCH
OncoTargets and Therapy
Publisher: DOVE MEDICAL PRESS LTD
Oncology Letters
Publisher: SPANDIDOS PUBL LTD
Cancers
Publisher: MDPI
Oncotarget
Publisher: Impact Journals
Cancer Management and Research
Publisher: DOVE MEDICAL PRESS LTD
Oncology Reports
Publisher: SPANDIDOS PUBL LTD
Annals of Oncology
Publisher: ELSEVIER
Journal of Clinical Oncology
Publisher: LIPPINCOTT WILLIAMS & WILKINS
0 Journals Selected to compare with
Anti-Cancer Drugs
Compare journals across 7 parameters SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
SJR Ranking, Topics covered, Indexing Database, Publication Review Time, Publication Type, Article Processing Charges & Recently Published papers
Get detailed Journal comparison report on your email by signing up
FAQs on Anti-Cancer Drugs
How long has Anti-Cancer Drugs been actively publishing? 
Anti-Cancer Drugs has been in operation since 1990 till date.
What is the publishing frequency of Anti-Cancer Drugs?
Anti-Cancer Drugs published with a Monthly frequency.
How many articles did Anti-Cancer Drugs publish last year?
In 2023, Anti-Cancer Drugs publsihed 85 articles.
What is the eISSN & pISSN for Anti-Cancer Drugs?
For Anti-Cancer Drugs, eISSN is 1473-5741 and pISSN is 0959-4973.
What is Citescore for Anti-Cancer Drugs?
Citescore for Anti-Cancer Drugs is 5.2.
What is the H Index for Anti-Cancer Drugs ?
H Index for Anti-Cancer Drugs is 98.
What is SNIP score for Anti-Cancer Drugs?
SNIP score for Anti-Cancer Drugs is 0.52.
What is the SJR for Anti-Cancer Drugs?
SJR for Anti-Cancer Drugs is Q3.
Who is the publisher of Anti-Cancer Drugs?
LIPPINCOTT WILLIAMS & WILKINS is the publisher of Anti-Cancer Drugs.
Your document is 100% secure & confidential 
